brothers-457237_960_720

The cause of the most common form of childhood cancer found

May 22, 2018
Manufacturing and Production, Research and Development biotech, drugs, leukaemia, pharma, pharmaceutical

Professor Mel Greaves, of The Institute of Cancer Research, has spent 30 years uncovering what is behind the mysterious rise …

landing-hero-images1

ViiV’s two-drug regimen gets EU approval for HIV-1

May 22, 2018
Manufacturing and Production, Sales and Marketing EMA, EU, Europe, HIV, Juluca, ViiV Healthcare, pharma

ViiV Healthcare has announced that its HIV therapy Juluca (dolutegravir/rilpivirine) has been awarded marketing authorisation in the EU from the …

pills_shot

Nabriva closes in on bringing new class of antibiotic to market

May 22, 2018
Manufacturing and Production, Sales and Marketing Antibiotics, Nabriva Therapeutics, biotech, drugs, pharma, pharmaceutical

Nabriva Therapeutics, a biotech based in Dublin, Ireland, has announced positive Phase 3 data for its antibiotic, lefamulin, which could …

gilead-sciences

Gilead expands operations in Cork, Ireland

May 21, 2018
Manufacturing and Production, Sales and Marketing Gilead, Ireland, biotech, drugs, pharma, pharmaceutical

Gilead has unveiled the expansion of its Cork manufacturing site, involved in the creation of its treatments for HIV and …

european_commission_web

EMA review confirms risks of Abbvie and Biogen’s Zinbryta outweigh benefits

May 21, 2018
Research and Development, Sales and Marketing EMA, Europe, European Commission, PRAC, multiple sclerosis, pharma, zinbryta

The EMA has judged that the benefits offered by Zinbryta (daclizumab), Abbvie and Biogen’s humanised IgG1 monoclonal antibody for the …

roche

Roche’s Hemlibra stakes claim to be haemophilia market leader

May 21, 2018
Research and Development, Sales and Marketing Hemlibra, Roche, Shire, biotech, drugs, haemophilia, pharma, pharmaceutical

Hemlibra was widely expected to become the dominant therapeutic for treating haemophilia patients and its latest clinical trial results only …

astrazeneca_sign_sky

FDA approves AZ’s Lokelma for hyperkalaemia

May 21, 2018
Sales and Marketing AstraZeneca, FDA, Lokelma, hyperkalaemia, pharma

The FDA has revealed its decision to approve AstraZeneca’s oral potassium-removing agent Lokelma (sodium zirconium cyclosilicate) for the treatment of …

greek_parliament

Investigation of kickbacks in Greece sputters to halt

May 21, 2018
Sales and Marketing Greece, Novartis, biotech, drugs, pharma, pharmaceutical

Greek parliament has decided against investigating allegations of bribery, involving Novartis and numerous high-level former politicians. The case has dominated …

4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

May 18, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, FDA, Novartis, Takeda, Trump, brexit, pharma, pharmafile, top ten

The year is flying by – it’s another Friday, and that means another Top Ten run-down.Perhaps the biggest story this …

ebola

Ebola threat intensifies in DR Congo

May 18, 2018
Medical Communications Ebola, MSD, biotech, drugs, pharma, pharmaceutical

The Ebola outbreak in the Democratic Republic of Congo is becoming increasingly serious, after it was confirmed that there was …

Pfizer’s Lyrica achieves endpoint as adjunct in paediatric epilepsy

May 18, 2018
Medical Communications, Research and Development FDA, Lyrica, Pfizer, epilepsy, pharma

Pfizer has revealed new Phase 3 data for its oral epilepsy therapy Lyrica (pregbalin) as an adjunctive treatment for partial …

headache

Amgen/Novartis potential blockbuster migraine med gets FDA nod

May 18, 2018
Medical Communications, Sales and Marketing Allergan, Amgen, Novartis, biotech, drugs, migraine, pharma, pharmaceutical

The first in a new class of migraine treatments has just received approval from the FDA; Amgen and Novartis’ Aimovig …

Study finds Herceptin use can be halved

May 17, 2018
Medical Communications, Research and Development Herceptin, Roche, biosimilars, biotech, drugs, pharma, pharmaceutical

A team of researchers from the University of Cambridge and Warwick Clinical Trials have revealed that Roche’s Herceptin is just …

ethan__drew_web

Living with an undiagnosed condition

May 17, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing feature, patient experience, pharma

Samantha O’Shea explains some of the challenges she faces caring for her son, Ethan, who lives with a debilitating but …

amgen_hq

Europe expands approved indication of Amgen’s Repatha in cardiovascular disease

May 17, 2018
Sales and Marketing Amgen, Repatha, cardiovascular disease, pharma

Amgen has revealed that its PCSK9 inhibitor Repatha (evolocumab) has received approval from the European Commission in a new indication: …

Ipsen receives European first-line approval for Cabometyx

May 17, 2018
Sales and Marketing Cabometyx, biotech, drugs, ipsen, pharma, pharmaceutical

Ipsen has revealed that it has received approval for the use of Cabometyx for first-line use in patients with advanced …

opioid_therapy_credit_-_us_air_force_valerie_monroy

FDA green lights first non-opioid therapy to manage symptoms of opioid withdrawal

May 17, 2018
Sales and Marketing FDA, Lucemyra, opioid crisis, opioids, pharma

As the opioid epidemic continues to grip the US as the leading cause of deaths in those under the age …

brexit_flag_0

UK MPs call for Brexit priority over pharma industry

May 17, 2018
Medical Communications ABPI, UK government, biotech, drugs, pharma, pharmaceutical

A new report published by the Business, Energy and Industrial Strategy Committee has called for the UK government to ensure …

roche_close

Roche gets NICE approval for advanced bladder cancer

May 17, 2018
Sales and Marketing Roche, biotech, drugs, pharma, pharmaceutical, tecentriq

Though trial results for Tecentriq (atezolizumab) may not necessarily be going Roche’s way, after a combination treatment failure, the treatment …

The Gateway to Local Adoption Series

Latest content